Antifibrinolytic Drugs Market Report by Indication (Gynecology, Hereditary Angioedema, Fibrinolytic Response Testing, Surgeries, and Others), Form (Oral, Injectable), End User (Hospitals and Clinics, Ambulatory Surgical Centers, Trauma Centers, and Others), and Region 2026-2034

Antifibrinolytic Drugs Market Report by Indication (Gynecology, Hereditary Angioedema, Fibrinolytic Response Testing, Surgeries, and Others), Form (Oral, Injectable), End User (Hospitals and Clinics, Ambulatory Surgical Centers, Trauma Centers, and Others), and Region 2026-2034

Report Format: PDF+Excel | Report ID: SR112026A5672

Market Overview:

The global antifibrinolytic drugs market size reached USD 18.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 25.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.47% during 2026-2034.

Report Attribute 
Key Statistics
Base Year
2025
Forecast Years
2026-2034
Historical Years
2020-2025
Market Size in 2025
USD 18.3 Billion
Market Forecast in 2034
USD 25.1 Billion
Market Growth Rate 2026-2034 3.47%

Antifibrinolytic drugs refer to the pharmaceutical medicines used for promoting the formation of blood clots to prevent fibrinolysis or blockage in arteries and veins. These drugs inhibit the activation of plasminogen, thereby preventing the lysis of fibrin and maintaining clot stability. They are used for the treatment of hemorrhages, vascular tumors and providing relief from heavy menstrual bleeding. They are also used for controlling bleeding during or after invasive surgeries. Some commonly available antifibrinolytic drugs include tranexamic acid, aprotinin, aminocaproic acid and serine protease inhibitors. They are widely used for the management of mucosal bleeding in the oropharynx, nose, gastrointestinal (GI) tract and uterine-vaginal linings. As a result, they are extensively used across hospitals, clinics and trauma and ambulatory surgical centers.

Antifibrinolytic Drugs Market Size

To get more information on this market Request Sample

Antifibrinolytic Drugs Market Trends:

The rising incidence of road accidents, traumas and various bleeding disorders is one of the key factors driving the growth of the market. Moreover, the widespread adoption of antifibrinolytic drugs to prevent blood loss in women suffering from menorrhagia and during cardiovascular and neurosurgeries is providing a thrust to the market growth. Antifibrinolytic drugs are essential for preventing clot lysis and minimizing blood loss. In line with this, increasing health consciousness and awareness among the masses regarding the available treatment alternatives for hereditary angioedema and hemophilia are also contributing to the growth of the market. Various technological advancements and the increasing utilization of antifibrinolytic therapy to reduce transfusion in orthopedic patients are acting as other growth-inducing factors. Pharmaceutical manufacturers are also developing innovative oral and intravenous drug variants with enhanced efficacy and bio-absorbability. Other factors, including the rising geriatric population and significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antifibrinolytic drugs market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on indication, form and end user.

Breakup by Indication:

  • Gynecology
  • Hereditary Angioedema
  • Fibrinolytic Response Testing
  • Surgeries
  • Others
     

Breakup by Form:

  • Oral
  • Injectable
     

Breakup by End User:

Antifibrinolytic Drugs Market By End User

Access the comprehensive market breakdown Request Sample

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Trauma Centers
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ACIC Pharmaceuticals Inc., Akorn Inc., Aurobindo Pharma Limited, Ferring Pharmaceuticals, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Viatris Inc. and Vitruvias Therapeutics Inc.

Report Coverage:

Report Features Details
Base Year of the Analysis 2025
Historical Period 2020-2025
Forecast Period 2026-2034
Units  Billion USD
Segment Coverage Indication, Form, End User, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered ACIC Pharmaceuticals Inc., Akorn Inc., Aurobindo Pharma Limited, Ferring Pharmaceuticals, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Viatris Inc. and Vitruvias Therapeutics Inc.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The antifibrinolytic drugs market was valued at USD 18.3 Billion in 2025.

We expect the global antifibrinolytic drugs market to exhibit a CAGR of 3.47% during 2026-2034.

The rising incidence of road accidents, traumas, and various bleeding disorders, along with the increasing adoption of antifibrinolytic drugs for preventing blood loss in women suffering from menorrhagia, is primarily driving the global antifibrinolytic drugs market.

The sudden outbreak of the COVID-19 pandemic had led to the growing number of R&D activities pertaining to specialty generic drugs for combating the spread of the coronavirus infection, thereby negatively impacting the global market for antifibrinolytic drugs.

Based on the indication, the global antifibrinolytic drugs market can be bifurcated into gynecology, hereditary angioedema, fibrinolytic response testing, surgeries, and others. Currently, gynecology exhibits a clear dominance in the market.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global antifibrinolytic drugs market include ACIC Pharmaceuticals Inc., Akorn Inc., Aurobindo Pharma Limited, Ferring Pharmaceuticals, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Viatris Inc., and Vitruvias Therapeutics Inc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Antifibrinolytic Drugs Market Report by Indication (Gynecology, Hereditary Angioedema, Fibrinolytic Response Testing, Surgeries, and Others), Form (Oral, Injectable), End User (Hospitals and Clinics, Ambulatory Surgical Centers, Trauma Centers, and Others), and Region 2026-2034
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-201-971-6302

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials